Skip to main content


You are here

Medcura Launches a New Class of High-Performance, Antibacterial Hemostats

Monday, July 12, 2021

RIVERDALE, Md., July 12, 2021 /PRNewswire/ -- Medcura, Inc., a commercial-stage medical device company, in partnership with ASO, LLC, a major U.S. manufacturer and supplier of first aid products, announced today the launch of a high-performance, antibacterial hemostatic gel, Rapid-Seal®, available @ and on the shelves at a leading US drugstore chain.

Medcura's Food and Drug Administration (FDA) cleared wound gel enters the market as the first in a new class of products that provide rapid bleeding management and antibacterial capabilities to improve wound treatment, help fight infections of the wound and promote an environment for safe healing.  Medcura custom designed this product to meet the market demand for a clear gel that can be easily and precisely applied, especially for irregular injuries where bandages can be inconvenient, and powders are messy and can cause discomfort.  By combining more exact delivery and highly effective wound sealing, Medcura's gel provides the consumer with greater per use value.

Read the full release from Medcura.